激素难治性前列腺癌的治疗：多西他赛及其他疗法
The treatment of hormone-refractory prostate cancer: docetaxel and beyond.
作者信息
Petrylak Daniel P
出版信息
Rev Urol. 2006;8 Suppl 2(Suppl 2):S48-55.
Abstract
Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer.
摘要
两项随机临床试验表明，与雄激素剥夺治疗失败后使用米托蒽醌和泼尼松治疗的生存率相比，基于多西他赛的治疗可使生存率提高20%至24%。这些研究支持了美国食品药品监督管理局于2005年5月批准基于多西他赛的治疗用于转移性激素难治性前列腺癌的治疗。目前，激素难治性前列腺癌的临床试验主要致力于在基于多西他赛的治疗所带来的生存率提高的基础上进一步发展。本文总结了一些治疗晚期前列腺癌更有前景的治疗方法和方案。
相似文献
1
The treatment of hormone-refractory prostate cancer: docetaxel and beyond.
Rev Urol. 2006;8 Suppl 2(Suppl 2):S48-55.
2
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Clin Cancer Res. 2004 Dec 15;10(24):8147-51. doi: 10.1158/1078-0432.CCR-04-1402.
3
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Br J Cancer. 2006 Aug 21;95(4):457-62. doi: 10.1038/sj.bjc.6603287. Epub 2006 Aug 1.
4
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Can J Urol. 2005 Feb;12 Suppl 1:81-5.
5
New paradigms for advanced prostate cancer.
Rev Urol. 2007;9 Suppl 2(Suppl 2):S3-S12.
6
Future directions in the treatment of androgen-independent prostate cancer.
Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020.
7
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
8
Update in the management of patients with hormone-refractory prostate cancer.
Curr Opin Urol. 2005 May;15(3):157-62. doi: 10.1097/01.mou.0000165548.87039.ff.
9
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Urology. 2005 Jun;65(6 Suppl):2-7. doi: 10.1016/j.urology.2005.03.080.
10
Chemotherapy for advanced hormone refractory prostate cancer.
Urology. 1999 Dec;54(6A Suppl):30-5. doi: 10.1016/s0090-4295(99)00452-5.
引用本文的文献
1
Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
PLoS One. 2024 Apr 2;19(4):e0297043. doi: 10.1371/journal.pone.0297043. eCollection 2024.
2
Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer.
Cell Biosci. 2022 Dec 15;12(1):200. doi: 10.1186/s13578-022-00941-0.
3
Targeting Solid Lipid Nanoparticles with Anisamide for Docetaxel Delivery to Prostate Cancer: Preparation, Optimization, and Evaluation.
Iran J Pharm Res. 2021 Winter;20(1):327-338. doi: 10.22037/ijpr.2020.113436.14302.
4
Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.
Oncogenesis. 2019 Feb 19;8(3):14. doi: 10.1038/s41389-019-0122-6.
5
Dual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells.
Int J Oncol. 2017 Nov;51(5):1601-1610. doi: 10.3892/ijo.2017.4138. Epub 2017 Sep 27.
6
Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.
Int J Nanomedicine. 2017 Sep 19;12:6973-6984. doi: 10.2147/IJN.S139011. eCollection 2017.
7
Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Mol Cancer Res. 2017 Apr;15(4):457-466. doi: 10.1158/1541-7786.MCR-16-0392. Epub 2017 Jan 13.
8
27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells.
Med Oncol. 2016 Feb;33(2):12. doi: 10.1007/s12032-015-0725-5. Epub 2016 Jan 5.
9
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.
Onco Targets Ther. 2014 Feb 12;7:223-34. doi: 10.2147/OTT.S53524. eCollection 2014.
10
Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Asian J Androl. 2013 Jan;15(1):110-5. doi: 10.1038/aja.2012.110. Epub 2012 Nov 12.
本文引用的文献
1
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252.
2
A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.
J Transl Med. 2006 Jan 3;4:1. doi: 10.1186/1479-5876-4-1.
3
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
J Clin Oncol. 2005 Dec 1;23(34):8724-9. doi: 10.1200/JCO.2005.02.4448.
4
Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.
Anticancer Res. 2005 Nov-Dec;25(6B):4333-9.
5
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
Clin Prostate Cancer. 2005 Jun;4(1):55-60. doi: 10.3816/cgc.2005.n.013.
6
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
J Clin Oncol. 2004 Jun 1;22(11):2122-32. doi: 10.1200/JCO.2004.08.083.
7
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
J Clin Oncol. 2003 Feb 15;21(4):679-89. doi: 10.1200/JCO.2003.04.176.
8
The endothelin axis: emerging role in cancer.
Nat Rev Cancer. 2003 Feb;3(2):110-6. doi: 10.1038/nrc990.
9
Chemotherapy for androgen-independent prostate cancer.
Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):31-5. doi: 10.1053/suro.2002.35052.
10
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Semin Oncol. 2001 Aug;28(4 Suppl 15):49-55. doi: 10.1016/s0093-7754(01)90155-1.
Zotero 插件